PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance

Christina L Pranger; Judit Fazekas-Singer; Verena K Köhler; Isabella Pali-Schöll; Alessandro Fiocchi; Sophia N Karagiannis; Olatz Zenarruzabeitia; Francisco Borrego; Erika Jensen-Jarolim

doi:10.1111/all.14604

PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance

Christina L Pranger, Judit Fazekas-Singer, Verena K Köhler, Isabella Pali-Schöll, Alessandro Fiocchi, Sophia N Karagiannis, Olatz Zenarruzabeitia, Francisco Borrego, Erika Jensen-Jarolim

Dermatology

Medical University of Vienna
Institute of Science and Technology Austria, Am Campus 1, 3400, Klosterneuburg, Austria.
Allergy Division, Pediatric Hospital Bambino Gesù IRCCS, Piazza di Sant'Onofrio, 4, 00165, Roma, Vatican City, Italy.
St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, 9th Floor, Tower Wing, Guy's Hospital, London, SE1 9RT, United Kingdom.
Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London, United Kingdom.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Cruces Plaza, 48903, Barakaldo, Bizkaia, Spain.
Ikerbasque, Basque Foundation for Science, Maria Diaz de Haro 3, 6 solairua, 48013, Bilbao, Bizkaia, Spain.

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

33 Downloads (Pure)

Original language	English
Number of pages	4
Journal	Allergy
Volume	76
Issue number	5
DOIs	https://doi.org/10.1111/all.14604
Publication status	E-pub ahead of print - 14 Oct 2020

Access to Document

10.1111/all.14604

Pranger et al Accepted Allergy 14604Accepted author manuscript, 13 MBLicence: CC BY

Cite this

@article{7da2c954fa334c75b3c1af13a9df2c8d,

title = "PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance",

author = "Pranger, {Christina L} and Judit Fazekas-Singer and K{\"o}hler, {Verena K} and Isabella Pali-Sch{\"o}ll and Alessandro Fiocchi and Karagiannis, {Sophia N} and Olatz Zenarruzabeitia and Francisco Borrego and Erika Jensen-Jarolim",

note = "Funding Information: This work was supported by the Austrian Science Fund (FWF) grants MCCA W1248‐B30 and SFB F4606‐B28 to EJJ. CP received a short‐term research fellowship of the European Federation of Immunological Societies (EFIS‐IL) for a research visit at Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. VKK received an EFIS‐IL short‐term research fellowship for a research visit at King{\textquoteright}s College London. The research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS‐BRC‐1215‐20006) (SNK). The authors acknowledge support by the Medical Research Council (MR/L023091/1) (SNK); Breast Cancer Now (147; KCL‐BCN‐Q3)(SNK); Cancer Research UK (C30122/A11527; C30122/A15774) (SNK); Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135) (SNK); CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587) (SNK). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Additionally, this work was funded by Instituto de Salud Carlos III through the project {"}PI16/01223{"} (Co‐funded by European Regional Development Fund; “A way to make Europe”) to FB and by the Department of Health, Basque Government through the project “2019111031” to OZ. OZ is recipient of a Sara Borrell 2017 postdoctoral contract “CD17/00128” funded by Instituto de Salud Carlos III (Co‐funded by European Social Fund; “Investing in your future”). Funding Information: EJJ is founder and shareholder of Biomedical Int. R+D GmbH, Vienna, Austria, and business partner of Bencard Allergie GmbH, Germany as well as AllergyTherapeutics Ltd., UK, but has no COI in relation to the presented work. EJJ also holds patents in lipocalins including BLG for allergen immunotherapy. SNK is founder and shareholder of Epsilogen Ltd. and holds patents on IgE antibodies for cancer therapy. AF is conducting research supported by Danone SA and Hipp GmbH. He has been in the advisory boards of Abbott SA and Hipp GmbH over the last two years. The other authors have no potential conflicts of interest to disclose.",

year = "2020",

month = oct,

day = "14",

doi = "10.1111/all.14604",

language = "English",

volume = "76",

journal = "Allergy",

issn = "0105-4538",

publisher = "John Wiley and sons",

number = "5",

}

TY - JOUR

T1 - PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance

AU - Pranger, Christina L

AU - Fazekas-Singer, Judit

AU - Köhler, Verena K

AU - Pali-Schöll, Isabella

AU - Fiocchi, Alessandro

AU - Karagiannis, Sophia N

AU - Zenarruzabeitia, Olatz

AU - Borrego, Francisco

AU - Jensen-Jarolim, Erika

N1 - Funding Information: This work was supported by the Austrian Science Fund (FWF) grants MCCA W1248‐B30 and SFB F4606‐B28 to EJJ. CP received a short‐term research fellowship of the European Federation of Immunological Societies (EFIS‐IL) for a research visit at Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. VKK received an EFIS‐IL short‐term research fellowship for a research visit at King’s College London. The research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS‐BRC‐1215‐20006) (SNK). The authors acknowledge support by the Medical Research Council (MR/L023091/1) (SNK); Breast Cancer Now (147; KCL‐BCN‐Q3)(SNK); Cancer Research UK (C30122/A11527; C30122/A15774) (SNK); Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135) (SNK); CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587) (SNK). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Additionally, this work was funded by Instituto de Salud Carlos III through the project "PI16/01223" (Co‐funded by European Regional Development Fund; “A way to make Europe”) to FB and by the Department of Health, Basque Government through the project “2019111031” to OZ. OZ is recipient of a Sara Borrell 2017 postdoctoral contract “CD17/00128” funded by Instituto de Salud Carlos III (Co‐funded by European Social Fund; “Investing in your future”). Funding Information: EJJ is founder and shareholder of Biomedical Int. R+D GmbH, Vienna, Austria, and business partner of Bencard Allergie GmbH, Germany as well as AllergyTherapeutics Ltd., UK, but has no COI in relation to the presented work. EJJ also holds patents in lipocalins including BLG for allergen immunotherapy. SNK is founder and shareholder of Epsilogen Ltd. and holds patents on IgE antibodies for cancer therapy. AF is conducting research supported by Danone SA and Hipp GmbH. He has been in the advisory boards of Abbott SA and Hipp GmbH over the last two years. The other authors have no potential conflicts of interest to disclose.

PY - 2020/10/14

Y1 - 2020/10/14

UR - http://www.scopus.com/inward/record.url?scp=85090633802&partnerID=8YFLogxK

U2 - 10.1111/all.14604

DO - 10.1111/all.14604

M3 - Letter

C2 - 32990982

SN - 0105-4538

VL - 76

JO - Allergy

JF - Allergy

IS - 5

ER -

PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance

Access to Document

Other files and links

Cite this